These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 25541089)
1. The problems of antibiotic resistance in cystic fibrosis and solutions. López-Causapé C; Rojo-Molinero E; Macià MD; Oliver A Expert Rev Respir Med; 2015 Feb; 9(1):73-88. PubMed ID: 25541089 [TBL] [Abstract][Full Text] [Related]
2. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients. Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303 [TBL] [Abstract][Full Text] [Related]
3. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Taccetti G; Campana S; Festini F; Mascherini M; Döring G Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728 [TBL] [Abstract][Full Text] [Related]
4. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis. Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708 [TBL] [Abstract][Full Text] [Related]
5. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277 [TBL] [Abstract][Full Text] [Related]
6. Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis. Hansen C; Skov M Ther Adv Respir Dis; 2015 Feb; 9(1):16-21. PubMed ID: 25471692 [TBL] [Abstract][Full Text] [Related]
7. Antibiotic pressure compensates the biological cost associated with Pseudomonas aeruginosa hypermutable phenotypes in vitro and in a murine model of chronic airways infection. Alcalá-Franco B; Montanari S; Cigana C; Bertoni G; Oliver A; Bragonzi A J Antimicrob Chemother; 2012 Apr; 67(4):962-9. PubMed ID: 22294647 [TBL] [Abstract][Full Text] [Related]
8. Killing effect of nanoencapsulated colistin sulfate on Pseudomonas aeruginosa from cystic fibrosis patients. Sans-Serramitjana E; Fusté E; Martínez-Garriga B; Merlos A; Pastor M; Pedraz JL; Esquisabel A; Bachiller D; Vinuesa T; Viñas M J Cyst Fibros; 2016 Sep; 15(5):611-8. PubMed ID: 26708265 [TBL] [Abstract][Full Text] [Related]
15. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness. Pritchard MF; Powell LC; Jack AA; Powell K; Beck K; Florance H; Forton J; Rye PD; Dessen A; Hill KE; Thomas DW Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630204 [TBL] [Abstract][Full Text] [Related]
16. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Amin R; Lam M; Dupuis A; Ratjen F Pediatr Pulmonol; 2011 Jun; 46(6):554-8. PubMed ID: 21337727 [TBL] [Abstract][Full Text] [Related]
17. Phenotypic and Genotypic Adaptations in Pseudomonas aeruginosa Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy. Oakley JL; Weiser R; Powell LC; Forton J; Mahenthiralingam E; Rye PD; Hill KE; Thomas DW; Pritchard MF mSphere; 2021 Jan; 6(1):. PubMed ID: 33472983 [TBL] [Abstract][Full Text] [Related]